RARA and acute myeloid leukemia: Our observation that in vivo treatment with the pan-RAR antagonist AGN193109 delayed leukemogenesis and reduced stemness in an Evi1high, MA9-driven AML model even raises the possibility that some subgroups of AML may benefit from RAR antagonists.